Navigation Links
Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs
Date:7/23/2008

Study results pending publication in July print edition of Clinical

Chemistry, available on Web

INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide (NT-proBNP) confirms the potential value of NT-proBNP for risk stratification in predicting the risk of cardiovascular adverse events (CV-AE) in patients treated with non-steroidal anti-inflammatory drugs of the COX inhibitor class.

The complete results of the study, currently available at http://www.clinchem.org , are scheduled for publication in the July print edition of Clinical Chemistry.

Non-steroidal anti-inflammatory drugs (NSAIDs) -- for example, acetylsalicylic acid and ibuprofen -- are the best known inhibitors of COX (cyclo-oxygenase), an enzyme involved in the inflammation pathway. This inhibition provides relief from the symptoms of the inflammation process; for example, fever and pain.

These drugs are routinely used to treat patients with osteoarthritis, rheumatoid arthritis and other pathologies associated with inflammation. However, studies with newer NSAIDs such as the selective COX-2 inhibitors (also called coxibs) have resulted in concern that there might be an increase in the risk of heart attack, thrombosis or stroke associated with long-term, high-dosage use of coxibs. Traditional NSAIDs (tNSAIDs) demonstrate comparable risks in observational studies.

Cardiovascular risk could be predicted

A pilot study(1) examined whether the risk of CV-AE could be predicted by measuring the NT-proBNP concentration in patients taking anti-inflammatory drugs. Baseline samples were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days.

Cardiovascular adverse events -
'/>"/>

SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions ... of proprietary clinical grade hypothermic storage and ... and contract aseptic media manufacturer , today announced ... & Regenerative Medicine Congress 2013 this week in ... http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) Dr. Aby J. Mathew, BioLife,s ...
(Date:5/23/2013)... SAN DIEGO and PARIS ... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today ... V asodilator I ndependent S tenosis ... late breaking clinical trial session at EuroPCR 2013. These ...
(Date:5/23/2013)... LAUSANNE , Switzerland ... 23, 2013 Cenix BioScience, ... developer specialized in RNAi-, miRNA- and high content-driven ... biopharmaceutical group of companies with a focus on ... medical needs, including oncology and companion diagnostics, today ...
Breaking Medicine Technology:BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:5/23/2013)... 23, 2013 Jim Fitzpatrick just did ... Advertising developed yet another outside-of-the-box approach to reaching the ... he brings daily newscasts to the retail automotive industry, ... of a broadcast news format. , CBTNews.com is ... news. Co-anchors Bridget Everett and Russell Brown host the ...
(Date:5/23/2013)... 23, 2013 To better serve ... company, is pleased to announce the release of ... its pacesetting space division products. Provided by Koroseal, ... the new patterns and colors represent a sophisticated ... meetings with a team of Koroseal experts, Modernfold ...
(Date:5/23/2013)... now, little was scientifically known about the human potential ... for people who are suffering in a way that ... researchers at the Center for Investigating Healthy Minds at ... that adults can be trained to be more compassionate. ... Psychological Science , is the first to investigate whether ...
(Date:5/23/2013)... New techniques in imaging of brain activity developed ... Neurological Institute, and his colleagues lead to improved ... combination of electroencephalogram (EEG) and functional magnetic resonance ... the areas generating epileptic seizures, giving neurosurgeons a ... if appropriate. These results were presented at ...
(Date:5/23/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Physicians ... lung cancer now have more information to help with the ... that low-dose CT scans pick up significantly more lung tumors ... of smoking are at high risk for lung cancer, the ... have to consider the potential harm of radiation exposure when ...
Breaking Medicine News(10 mins):Health News:Fitzpatrick Advertising Founder Brings Auto Industry into Focus with CBT News 2Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:Study shows people can be trained to be more compassionate 2Health News:Study shows people can be trained to be more compassionate 3Health News:Study shows people can be trained to be more compassionate 4Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... Two stroke-prevention procedures are safe and equally beneficial for ... effectiveness does vary by age, say researchers at the ... other North American stroke investigators. In findings reported ... Antonio, Texas, the researchers say physicians now have better ...
... on routes they knew well , FRIDAY, Feb. 26 ... drivers can make fatal mistakes on familiar routes, German ... brain activity in 16 experienced and 16 less experienced ... the routes on the simulator, the participants, brains were ...
Cached Medicine News:Health News:Stroke Conference Daily News Summary -- Friday 2Health News:Stroke Conference Daily News Summary -- Friday 3Health News:Stroke Conference Daily News Summary -- Friday 4Health News:Stroke Conference Daily News Summary -- Friday 5Health News:Stroke Conference Daily News Summary -- Friday 6Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 2Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 3Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 4Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 5Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 6Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 7Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 2Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 3Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 4Health News:American National Announces Corrected Dividend Dates 2Health News:Study: Choice between stroke-prevention procedures influenced by patient age 2Health News:Study: Choice between stroke-prevention procedures influenced by patient age 3
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
The Pivot Bipolar was designed with a simple one-step assembly interface between the femoral head and the compression molded liner which requires no instruments and reduces OR time....
Medicine Products: